Research Reports

Key takeaways

Operating loss improved 6.7% to $16.9M, reflecting lower R&D spending as certain trials completed.

Net loss narrowed 9.6% to $14.5M, driven by the operating improvement and higher interest income.

Diluted EPS improved 37.1% to $(0.39) from $(0.62), benefiting from the reduced net loss.

Cash used in operations increased to $16.3M from $14.4M, primarily due to a decrease in accrued expenses.

Full analysis

Net Loss Narrows as Operating Loss Improves

Cash Burn Increases on Working Capital Changes

Strong Liquidity Position

Clinical Pipeline Progress and Outlook

The company continues to advance its pipeline, with drug candidates in later stages of clinical development generally incurring higher costs due to larger and longer trials. General and administrative expenses are expected to increase to support expanded research activities and public company operations. Contineum has incurred net losses and negative cash flows from operations in nearly every reporting period since inception and anticipates continuing losses for the foreseeable future.